✦ LIBER ✦

Cyclophosphamide, doxorubicin, vincristine, and low-dose continuous infusion bleomycin in non-Hodgkin's lymphoma: Cancer and leukemia group B study #7804

✍ Scribed by Sandra J. Ginsberg; Stanley T. Crooke; Clara D. Bloomfield; Bruce Peterson; B. J. Kennedy; Johannes Blom; Rose Ruth Ellison; Thomas F. Pajak; Arlan J. Gottlieb

Publisher: John Wiley and Sons
Year: 1982
Tongue: English
Weight: 568 KB
Volume: 49
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19820401)49:7<1346::aid-cncr2820490706>3.0.co;2-#

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dose-escalated cyclophosphamide, doxorub

Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma : Cancer and Leukemia Group B studies 8852 and 8854

✍ Nancy L. Bartlett; Gina R. Petroni; Barbara A. Parker; Nina D. Wagner; Jon P. Go 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 2 views

A randomized comparison of methotrexate

A randomized comparison of methotrexate dose and the addition of bleomycin to chop therapy for diffuse large cell lymphoma and other non-Hodgkin's lymphomas cancer and leukemia group B study 7851

✍ Arlan J. Gottlieb; James R. Anderson; Sandra J. Ginsberg; Clara D. Bloomfield; L 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 771 KB

Phase II trial of ifosfamide and mesna i

Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8552

✍ Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 481 KB

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and

Phase II trial of ifosfamide and mesna i

Phase II trial of ifosfamide and mesna in previously treated patients with non-hodgkin's lymphoma: Cancer and leukemia group b study 8552

✍ Delvyn C. Case JR; James Anderson; Thomas J. Ervin; Arlan Gottlieb 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 522 KB

## Abstract Ifosfamide (1·25 g/m^2^ intravenously/day × 5) with mesna (20 per cent of the ifosfamide dose × six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non‐Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29 per cent response rat

Phase II trial of etoposide and cisplati

Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and leukemia group B study 8351

✍ Rybak, Mary Ellen ;Anderson, James ;Kaplan, Richard ;Budman, Daniel R. ;Vincigue 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB

## Abstract A phase‐II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed non‐Hodgkin's lymphoma (NHL) to assess the activity of the combination of etoposide and cisplatin. Sixty‐five patients were entered on study, and 51 patients were evaluated

Phase II trial of ifosfamide/mesna and m

Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8753

✍ Case, Delvyn C. ;Santarelli, Maria Teresa ;Carey, Robert W. ;Anderson, James ;Go 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 461 KB

## Abstract Ifosfamide (2.0 g/m^2^ intravenously/day × 3) with mesna (400 mg/m^2^ intravenously q 4 h daily × 3) was combined with mitoxantrone (14 mg/m^2^ intravenously × 1) and given on a 3 week schedule to patients with previously treated non‐Hodkgin's lymphoma. In 45 eligible/evaluable patients